Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
The Ixion 2.0 study is looking into a potential new treatment called FX06 for people who have Acute Respiratory Distress Syndrome (ARDS). ARDS is a very serious lung condition where the lungs become inflamed and struggle to provide enough oxygen to the body, often requiring breathing support. The main goal of this study is to find out if patients receiving FX06 are able to breathe without assistance more quickly than those who receive a placebo, which is an inactive substance that looks just like the treatment. Researchers will be following patients for up to 28 days to see if the new treatment makes a difference to their recovery and overall health.
At a glance
What is this study about?
This research is focused on a serious lung problem called Acute Respiratory Distress Syndrome, or ARDS. ARDS can happen when a person becomes very ill, for example, from a severe infection, and their lungs get very inflamed. This inflammation makes it hard for the lungs to work properly, and patients often need help from a breathing machine (ventilator) to get enough oxygen. It's a life-threatening condition.
The study, called Ixion 2.0, is looking at a new potential treatment named FX06. The main idea behind this study is to see if FX06 can help people with ARDS recover and start breathing on their own again more quickly. By getting off breathing support sooner, patients might have a better recovery overall.
To see if FX06 works, some patients in the study will receive FX06, while others will get a placebo. A placebo looks exactly like the real treatment but contains no active medicine. This comparison helps researchers determine if any improvements are due to FX06 itself, rather than other factors. They will carefully monitor how long it takes for patients in both groups to breathe without a ventilator. This is a "Phase II" study, meaning it's an early stage of testing to see if the treatment is safe and shows promise.
Key takeaways
- The study explores a new treatment (FX06) for severe lung disease (ARDS).
- It aims to help patients breathe on their own sooner.
- Some patients receive FX06, others a dummy treatment (placebo).
- Close monitoring over 28 days measures recovery and safety.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
To be considered for this study, you must be at least 18 years old. Both men and women are welcome to take part. The study is specifically for patients who have been diagnosed with Acute Respiratory Distress Syndrome (ARDS).
The researchers will also look at your overall health, any other medical conditions you have, and the medicines you are currently taking to make sure it's safe for you to participate. If you're interested, the study team will go through a full checklist with you and your doctors to confirm if you meet all the requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Acute Respiratory Distress Syndrome (ARDS)?
- Are you currently in a hospital setting where the study is active?
- Do your doctors believe this study might be suitable for your condition?
What does participation involve?
If you decide to take part in this study, you will either receive the study drug FX06 or a placebo (a dummy treatment). You won't know which one you are getting, and neither will your doctors – this is standard practice to make the study fair. The treatment will be given to you in the hospital. The study team will closely monitor you, taking regular measurements like your breathing, how well your lungs are working, and checking your blood. They will also look at how long you stay in the hospital and intensive care unit (ICU).
Doctors will regularly check your blood for signs of inflammation and how well your organs are functioning. They will also assess your overall recovery. The main part of the study will involve monitoring for up to 28 days to see how quickly you can breathe on your own. There may be follow-up checks after this period. The full duration of your participation will depend on your recovery, but the key measurements are taken up to day 28.
Potential risks and benefits
Locations (5)
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedRomania
- —UnverifiedGermany
- —UnverifiedLithuania
Common questions
What is ARDS?
ARDS (Acute Respiratory Distress Syndrome) is a severe lung condition where the lungs become inflamed, making it difficult to breathe and get enough oxygen. It often requires hospital care and breathing support.
What is FX06?
FX06 is a new substance being investigated as a potential treatment for ARDS. This study aims to see if it can help patients recover faster.
What is a 'placebo'?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active ingredients. It's used to fairly compare the effects of the new treatment.
Will I know if I'm getting FX06 or the placebo?
No, neither you nor your doctors will know if you are receiving FX06 or the placebo. This helps ensure the study results are unbiased.
How long will I be in the study?
The key measurements will be taken over 28 days, focusing on how quickly you can breathe independently. Your overall time in the study might vary.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.